Literature DB >> 24472065

Endoscopic ultrasound in patients with normal liver blood tests and unexplained dilatation of common bile duct and or pancreatic duct.

Kofi W Oppong1, Vikramjit Mitra, John Scott, Kirsty Anderson, Richard M Charnley, Stuart Bonnington, Bryon Jaques, Steven White, Jeremy J French, Derek M Manas, Gourab Sen, Manu K Nayar.   

Abstract

OBJECTIVE: To determine the yield of endoscopic ultrasound (EUS) in the investigation of patients with normal liver function tests (LFTs) and unexplained dilatation of common bile duct (CBD) and/or pancreatic duct (PD), following CT and/or magnetic resonance cholangiopancreatography.
MATERIALS AND METHODS: Consecutive patients undergoing linear EUS between January 2007 and August 2011 for the indication of dilated CBD and/or PD, normal LFT, and nondiagnostic cross-sectional imaging formed the study group. The study was performed as a retrospective analysis of prospectively collected data.
RESULTS: During the study period, 83 patients (CBD and PD dilatation n = 38, PD dilatation n = 5, CBD dilatation n = 40) met the inclusion criteria and underwent EUS. Five (13.1%) of the CBD and PD groups had a new finding, which in one (2.6%) case was causal. In this group, men were significantly more likely to have a new finding (p = 0.012). Eight (20%) of the CBD group had a new finding, which in seven (17.5%) cases was causal. In the CBD group, cholecystectomy was significantly (p = 0.005) more common in those without a finding. Three (60%) of the PD group had a finding on EUS, all of which were causal, including a case of pancreatic malignancy.
CONCLUSION: There is a significant yield from EUS in individuals with isolated PD dilatation and isolated CBD dilatation. Previous cholecystectomy is significantly associated with a negative EUS in the group with isolated CBD dilatation. The yield in those with CBD and PD dilatation was low and a finding was more likely in males.

Entities:  

Mesh:

Year:  2014        PMID: 24472065     DOI: 10.3109/00365521.2014.881547

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

Review 1.  Endoscopic ultrasound in common bile duct dilatation with normal liver enzymes.

Authors:  Claudio De Angelis; Milena Marietti; Mauro Bruno; Rinaldo Pellicano; Mario Rizzetto
Journal:  World J Gastrointest Endosc       Date:  2015-07-10

2.  Advancing the diagnostic and therapeutic role of EUS in pancreaticobiliary disease: Hopkins Lecture 2016.

Authors:  Kofi Oppong
Journal:  Frontline Gastroenterol       Date:  2016-11-17

Review 3.  Ultrasound findings in paediatric cholestasis: how to image the patient and what to look for.

Authors:  Marco Di Serafino; Matilde Gioioso; Rosa Severino; Francesco Esposito; Norberto Vezzali; Federica Ferro; Piernicola Pelliccia; Maria Grazia Caprio; Raffaele Iorio; Gianfranco Vallone
Journal:  J Ultrasound       Date:  2019-02-12

4.  Malignant biliary strictures in patients with a normal bilirubin and/or normal liver enzymes.

Authors:  Sarah C Thomasset; David Saunders; Adele Holland; Ashley R Dennison; Giuseppe Garcea
Journal:  HPB (Oxford)       Date:  2015-08-07       Impact factor: 3.647

5.  Combining endoscopic ultrasound and tumor markers improves the diagnostic yield on the etiology of common bile duct dilation secondary to periampullary pathologies.

Authors:  Han Ding; Pinghong Zhou; Meidong Xu; Weifeng Chen; Quanlin Li; Tao Chen; Mingyan Cai; Tianyin Chen; Jingjing Lian; Yiqun Zhang
Journal:  Ann Transl Med       Date:  2019-07

6.  Asymptomatic Bile Duct Dilatation in Children: Is It a Disease?

Authors:  Yeo Ju Son; Mi Jung Lee; Hong Koh; Seung Kim
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2015-09-25

7.  Diagnostic Value of Endoscopic Ultrasonography for Common Bile Duct Dilatation without Identifiable Etiology Detected from Cross-Sectional Imaging.

Authors:  Nonthalee Pausawasdi; Penprapai Hongsrisuwan; Lubna Kamani; Kotchakon Maipang; Phunchai Charatcharoenwitthaya
Journal:  Clin Endosc       Date:  2022-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.